Literature DB >> 7597446

Histopathology of hepatitis C virus infection.

Z D Goodman1, K G Ishak.   

Abstract

Hepatitis C can cause a range of hepatic histopathology. The virus may cause an acute hepatitis indistinguishable from any other acute viral hepatitis, but it is more likely to be associated with steatosis, bile duct injury, and portal lymphoid aggregates. Chronic infection with hepatitis C can range from mild nonspecific changes, presumably representing a hepatitis C carrier state, to end-stage liver disease with cirrhosis and hepatocellular carcinoma. Between these are chronic hepatitis of varying severity. Steatosis, portal lymphoid aggregates, and bile duct injury, while not specific, are very characteristic of chronic hepatitis C. Reputed precursors of hepatocellular carcinoma, including liver cell dysplasia and adenomatous hyperplasia, frequently follow the development of cirrhosis and are presumed to predispose to the development of malignancy. New techniques for localizing the virus in liver tissue will undoubtedly lead to greater understanding of the pathogenesis of hepatitis C-related diseases.

Entities:  

Mesh:

Year:  1995        PMID: 7597446     DOI: 10.1055/s-2007-1007264

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  43 in total

1.  The Effect Of Long Term and High Dose Interferon Treatment In Chronic Hepatitis C.

Authors:  Gábor Horváth; Gyula Stotz; Gyula Tolvaj; Henrik Osztrogonácz; Károly Dávid
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 2.  Current status of hepatitis C in Canada.

Authors:  S Zou; M Tepper; A Giulivi
Journal:  Can J Public Health       Date:  2000 Jul-Aug

3.  A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans.

Authors:  S M Lemon; H Lerat; S A Weinman; M Honda
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

4.  Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease.

Authors:  Hongfa Zhu; Henry C Bodenheimer; David J Clain; Albert D Min; Neil D Theise
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

5.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

6.  Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C.

Authors:  Norah J Shire; Meng Yin; Jun Chen; Radha A Railkar; Sabrina Fox-Bosetti; Stephanie M Johnson; Chan R Beals; Bernard J Dardzinski; Schuyler O Sanderson; Jayant A Talwalkar; Richard L Ehman
Journal:  J Magn Reson Imaging       Date:  2011-07-12       Impact factor: 4.813

7.  Fatty liver in chronic hepatitis C infection: unravelling the mechanisms.

Authors:  Jude A Oben; Emma Paulon
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

8.  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.

Authors:  Masao Omata; Haruhiko Yoshida; Joji Toyota; Eiichi Tomita; Shuhei Nishiguchi; Norio Hayashi; Shiro Iino; Isao Makino; Kiwamu Okita; Gotaro Toda; Kyuichi Tanikawa; Hiromitsu Kumada
Journal:  Gut       Date:  2007-06-15       Impact factor: 23.059

9.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

10.  Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C.

Authors:  Ajay Duseja; R K Dhiman; Yogesh Chawla; Kiran K Thumburu; Amit Kumar; Ashim Das; Sanjay Bhadada; Anil Bhansali
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.